Needham analyst Michael Matson maintained a Buy rating on Boston Scientific Corp (BSX) today and set a price target of $43. The company’s shares opened today at $38.10.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 11.8% and a 66.3% success rate. Matson covers the Healthcare sector, focusing on stocks such as Cardiovascular Systems, Zimmer Biomet Holdings, and Merit Medical Systems.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Boston Scientific Corp with a $44.53 average price target, implying a 16.9% upside from current levels. In a report issued on April 1, Raymond James also maintained a Buy rating on the stock with a $44 price target.
See today’s analyst top recommended stocks >>
Boston Scientific Corp’s market cap is currently $52.35B and has a P/E ratio of 31.77. The company has a Price to Book ratio of 6.00.
Based on the recent corporate insider activity of 159 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Cardiovascular, Rhythm Management, and MedSurg.
